柳叶刀TheLancet|格卡瑞韦/哌仑他韦治疗慢性丙型肝炎亚裔患者:两项多中心三期研究( 二 )


Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China (Prof L Wei MD); Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China (Prof L Wei); Peking University First Hospital, Beijing, China (Prof G Wang MD); AbbVie, North Chicago, IL, USA (N N Alami MD, L M Fredrick MS, W Lu PhD, W Liu PhD, H V Kalluri PhD, P Krishnan PhD, R Tripathi MS, N Mobashery MD, M Burroughs MD, A Asatryan MD); Center of Liver Diseases, Beijing Di Tan Hospital, Capital Medical University, Beijing, China; (Prof W Xie MD); Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, South Korea (Prof J Heo MD); Department of Infectious Diseases,Rui Jin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China (Prof Q Xie MD); Shenyang Sixth People’s Hospital, Shenyang, China (Prof M Zhang MD); Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea (Prof Y J Kim MD); National University Healthcare System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (Prof S G Lim MD); Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China (Prof J Jia MD); and Department of Infectious Diseases and Hepatology Unit, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China (Prof J Hou MD)
Correspondence to: Prof Jinlin Hou, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, 510515 China
jlhousmu@163.com
*中文翻译仅供参考 , 所有内容以英文原文为准 。


推荐阅读